Angiotensin II

Rinaldo Bellomo^{1

2

3

4

5}, Alexander Zarbock⁶, Giovanni Landoni^{7

8}

Affiliations

¹ Australian and New Zealand Intensive Care Research Centre (ANZIC-RC), School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia. Rinaldo.bellomo@austin.org.au.
² Department of Critical Care, University of Melbourne, Melbourne, Australia. Rinaldo.bellomo@austin.org.au.
³ Data Analytics Research and Evaluation Centre, Austin Hospital, Melbourne, Australia. Rinaldo.bellomo@austin.org.au.
⁴ Department of Intensive Care, Austin Hospital, Heidelberg, Melbourne, VIC, 3084, Australia. Rinaldo.bellomo@austin.org.au.
⁵ Department of Intensive Care, Royal Melbourne Hospital, Melbourne, Australia. Rinaldo.bellomo@austin.org.au.
⁶ Department of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Münster, Münster, Germany.
⁷ Vita-Salute San Raffaele University, Milan, Italy.
⁸ IRCCS San Raffaele Scientific Institute, Milan, Italy.

Editorial

Rinaldo Bellomo et al. Intensive Care Med. 2024 Feb.

. 2024 Feb;50(2):279-282.

doi: 10.1007/s00134-023-07290-7. Epub 2024 Jan 8.

Rinaldo Bellomo^{1

2

3

4

5}, Alexander Zarbock⁶, Giovanni Landoni^{7

8}

¹ Australian and New Zealand Intensive Care Research Centre (ANZIC-RC), School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia. Rinaldo.bellomo@austin.org.au.
² Department of Critical Care, University of Melbourne, Melbourne, Australia. Rinaldo.bellomo@austin.org.au.
³ Data Analytics Research and Evaluation Centre, Austin Hospital, Melbourne, Australia. Rinaldo.bellomo@austin.org.au.
⁴ Department of Intensive Care, Austin Hospital, Heidelberg, Melbourne, VIC, 3084, Australia. Rinaldo.bellomo@austin.org.au.
⁵ Department of Intensive Care, Royal Melbourne Hospital, Melbourne, Australia. Rinaldo.bellomo@austin.org.au.
⁶ Department of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Münster, Münster, Germany.
⁷ Vita-Salute San Raffaele University, Milan, Italy.
⁸ IRCCS San Raffaele Scientific Institute, Milan, Italy.

No abstract available

References

1. Busse LW, Wang XS, Chalikonda DM, Finkel KW, Khanna AK, Szerlip HM et al (2017) Clinical experience with angiotensin II administration: a systematic review of safety. Crit Care Med 45:1285–1294 - DOI - PubMed - PMC
1. Wan L, Langenberg C, Bellomo R, May CN (2009) Angiotensin II in experimental hyperdynamic sepsis. Crit Care 13:R190 - DOI - PubMed - PMC
1. Chawla LS, Busse L, Brasha-Mitchell E, Davison D, Honiq J, Alotaibi Z et al (2014) Intravenous angiotensin II for the treatment of high-output shock (ATHOS trial): a pilot study. Crit Care 18:534 - DOI - PubMed - PMC
1. Chawla LS, Russell JA, Bagshaw SM, Shaw AD, Goldstein SL, Fink MP et al (2017) Angiotensin II for the treatment of high-output shock 3 (ATHOS-3): protocol for a phase III, double-blind, randomised controlled trial. Crit Care Resusc 19:43–49 - PubMed
1. Khanna A, English SW, Wang XS, Ham K, Tumlin J, Szerlip H et al (2017) Angiotensin II for the treatment of vasodilatory shock. New Engl J Med 377:419–430 - DOI - PubMed